Generic formulation of cyclosporine A, equoral®, in de novo kidney transplant recipients: Five-year follow-up

Annals of Transplantation

Volumn 16, Issue 2, 2011, Pages 59-62

  Niemczyk, Mariusz ^a   Paczek, Leszek ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Cyclosporine a; Equoralspi_sup spii_sup; Follow up; Graft survival; Kidney transplantation; Patient survival

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EQUORAL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; DRUG FORMULATION; FEMALE; FOLLOW UP; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERURICEMIA; KIDNEY DISEASE; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; RETROSPECTIVE STUDY; SEPSIS;

EID: 79960078014     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/AOT.881866     Document Type: Article

References (12)

1. Andrysek T, Masri M, Jegorov A et al: Equoral, new cyclosporine drug delivery system, versus Neoral: A bioequivalence study in healthy volunteers. Transplant Proc, 2003; 35: 207-9
2. Masri MA, Haberal M, Rizvi A et al: Switchability of Neoral and Equoral according to Food and Drug Administration rules and regulations. Transplant Proc, 2005; 37: 2988-93
3. Perlik F, Masri MA, Rost M, Kamarad V: Pharmacokinetics conversion study of a new cyclosporine formulation in stable adult renal transplant recipients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2005; 149: 309-13
4. Zadrazil J, Al Jabry S, Bachleda P, Gibejova A: Use of Equoral in de novo renal transplant recipients. Biomed Papers, 2004; 148: 171-73
5. Spasovski G, Masin-Spasovska J, Ivanovski N: Do we have the same clinical results with Neoral and Equoral treatment in kidney transplant recipients? A pilot study. Transpl Int, 2008; 21: 392-94
6. Diarra DA, Riegersperger M, Säemann MD, Sunder- Plassmann G: Maintenance immunosuppressive therapy and generic cyclosporine A use in adult renal transplantation: a single center analysis. Kidney Int Suppl, 2010; 115: S8-11
7. Vítko S, Ferkl M: Interchangeability of ciclosporin formulations in stable adult renal transplant recipients: comparison of Equoral and Neoral capsules in an international, multicenter, randomized, openlabel trial. Kidney Int Suppl, 2010; 115: S12-16
8. Durlik M, Paczek L, Rutkowski B et al: The efficacy and safety of ciclosporin (Eqoural®) capsules after renal transplantation: A multicentre, open-label, phase IV clinical trial. Ann Transplant, 2010; 15: 51-59
9. Vincenti F, Jensik SC, Filo RS et al: A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: Evidence for improved allograft survival at five years. Transplantation, 2002; 73: 775-82
10. Anil Kumar MS, Irfan Saed M, Ranganna K et al: Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: Five-year outcomes. Transplant Immunol, 2008; 20: 32-42
11. Cheung CY, Chan HW, Liu YL et al: Long-term graft function with tacrolimus and cyclosporine in renal transplantation: Paired kidney analysis. Nephrology, 2009; 14: 758-63
12. Lee YJ, Kim B, Lee JE et al: Randomized trial of cyclosporine and tacrolimus therapy with steroid withdrawal in living-donor renal transplantation: 5-year follow-up. Transplant International, 2010; 23: 147-54